Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Raludotatug deruxtecan versus investigator's choice chemotherapy in platinum-resistant high-grade ovarian, primary peritoneal, or fallopian tube cancer
2023-507914-28-00Phase 3Authorised
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- May 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 19
01
Overview
Phase 3, randomised, open-label trial of raludotatug deruxtecan in ovarian cancer, primary peritoneal cancer (PPC) and fallopian tube cancer (PFTC) (2 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoints: Objective response rate and Progression-free survival. Planned start May 2024; status: authorised.
02
Drugs
raludotatug deruxtecan
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on 2023-507914-28-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507914-28-00.